Response to tigilanol tiglate in dogs with mast cell tumors.

Abstract

Background: Information regarding response rate to tigilanol tiglate for mast cell tumors in dogs is limited.

Objectives: Report the response rate and durability of tigilanol tiglate intratumoral treatment in dogs with mast cell tumors presented to veterinary oncologists.

Animals: One hundred forty-nine dogs; 151 individual tumors.

Methods: Multicenter, retrospective survey-based study. Veterinary oncologists subscribed to the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were solicited for information from dogs treated with tigilanol tiglate. An electronic survey was used to collect information at initial treatment, 1 month and 1 year after treatment.

Results: Most tumors were cutaneous, occurred on the limbs and were cytologically low grade. Seventy-five percent of dogs achieved a complete response after 1 dose of tigilanol tiglate 1 month after treatment. This response was durable at 1 year in 64% of dogs for which data were available (n = 88). Wound formation, an expectation after treatment, occurred after a median of 7 days (range, 1-91 days), with a median wound area of 4.71 cm² (range, 0.09-100 cm²). Wounds took a median of 30 days to heal completely (range, 14-154 days). A moderate association between tumor volume and wound size was confirmed.

Conclusions and clinical importance: Tigilanol tiglate is an effective local treatment option for mast cell tumors in dogs with a predictable clinical course and response. Because of the unique mode of action and clinical course, client education and careful case selection is necessary before electing tigilanol tiglate for local treatment.